Bronchodilators Market to Reach $41.48 Bn, Globally, by 2026 at 5.2% CAGR: Allied Market Research

Rise in prevalence of asthma and COPD, and increase in government initiatives fuel the growth of the global bronchodilators market

PORTLAND, Oregon, March 2, 2020 /PRNewswire/ -- Allied Market Research published a report, titled, "Bronchodilators Market by Drug class (Sympathomimetics, Anticholinergics, Phosphodiesterase Inhibitor and Combination Drugs), by Indication (Asthma, COPD, and Others), and Route of Administration (Oral, Injection, and Inhaler): Global Opportunity Analysis and Industry Forecast, 2019–2026." According to the report, the global bronchodilators industry was estimated at $27.58 billion in 2018 and is expected to hit $41.48 billion by 2026, registering a CAGR of 5.2% from 2019 to 2026.

Drivers, restraints & opportunities-

Rise in prevalence of asthma and COPD and increase in government initiatives drive the growth of the global bronchodilators market. On the other hand, several side effects associated with bronchodilators hamper the growth to some extent. Nevertheless, development in emerging economies is expected to create an array of opportunities in the near future.

Request Sample Report at: https://www.alliedmarketresearch.com/request-sample/3941

The asthma segment to retain its dominance during the estimated period-

Based on indication, the asthma segment accounted for more than one-fourth of the global bronchodilators market share in 2018, and is expected to dominate throughout the forecast period. The same segment would also grow at the fastest CAGR of 6.1% till 2026. This is attributed to significant increase in prevalence of asthma across the globe.

The anticholinergics segment to lead the trail during the study period-

Based on drug type, the anticholinergics segment held the highest share in 2018, garnering nearly half of the global bronchodilators market. This is due to increased usage of anticholinergic drugs for the treatment of respiratory problem that makes it hard for patients to breathe. The combination drugs segment, on the other hand, would cite the fastest CAGR of 5.9% during 2019–2026. This is attributed to their properties of dilating air passages that make air flow easier.

North America to rule the roost by 2026-

Based on geography, North America contributed to more than two-fifths of the global bronchodilators market revenue in 2018, and is anticipated to maintain the lion's share by the end of 2026. Rise in cystic fibrosis and increase in government initiates toward growing awareness of COPD, asthma, and other chronic respiratory disorders boost the market in the region. Simultaneously, the region across LAMEA would grow at the fastest CAGR of 9.2% by the end of 2026. Increase in geriatric population and upsurge in demand for quick & advanced treatment methodologies in the healthcare industry is anticipated to offer remunerative opportunities for the market in this province.

For Purchase Enquiry at: https://www.alliedmarketresearch.com/purchase-enquiry/3941

Key players in the market-

• GlaxoSmithKline
• Abbott Laboratories
• F AstraZeneca plc
• Novartis AG
• Boehringer Ingelheim
• Pfizer Inc.
• Hoffmann-La Roche AG
• Teva Pharmaceutical Industries Ltd.,
• Vectura Group plc

Avenue Basic Plan | Library Access | 1 Year Subscription |

Sign up for Avenue subscription to access more than 12,000+ company profiles and 2,000+ niche industry market research reports at $699 per month, per seat. For a year, the client needs to purchase minimum 2 seat plan.

Avenue Library Subscription | Request for 14 days free trial of before buying: https://www.alliedmarketresearch.com/avenue/trial/starter

Get more information: https://www.alliedmarketresearch.com/library-access

Similar Reports:

hCG Market - Global Opportunity Analysis and Industry Forecast, 2019-2026

Immunoglobulin Market- Global Opportunity Analysis and Industry Forecast, 2019-2027

OTC Drugs & Dietary Supplements Market- Global Opportunity Analysis & Industry Forecast, 2019-2027

Cephalosporin Market- Global Opportunity Analysis and Industry Forecast, 2019-2027

PEGylated Protein Therapeutics Market- Global Opportunity Analysis and Industry Forecast, 2020-2027

About Us

Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of "Market Research Reports" and "Business Intelligence Solutions." AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.

We are in professional corporate relations with various companies and this helps us in digging out market data that helps us generate accurate research data tables and confirms utmost accuracy in our market forecasting. Each and every data presented in the reports published by us is extracted through primary interviews with top officials from leading companies of domain concerned. Our secondary data procurement methodology includes deep online and offline research and discussion with knowledgeable professionals and analysts in the industry.

Contact:
David Correa
5933 NE Win Sivers Drive
#205, Portland, OR 97220
United States
USA/Canada (Toll Free): 1-800-792-5285, 1-503-894-6022, 1-503-446-1141
UK: +44-845-528-1300
Hong Kong: +852-301-84916
India (Pune): +91-20-66346060
Fax: +1(855)550-5975
help@alliedmarketresearch.com  
Web: https://www.alliedmarketresearch.com 
Life Science Market: https://www.alliedmarketresearch.com/reports-store/life-sciences 
Follow Us on LinkedIn: https://www.linkedin.com/company/allied-market-research

Logo: https://mma.prnewswire.com/media/636519/Allied_Market_Research_Logo.jpg